Cargando…
Loading, please waitCargando…
Loading, please waitCondition guide — AMD
A conservative, physician-led look at where regenerative medicine stands for age-related macular degeneration (AMD) — what mesenchymal stem cells can and cannot reasonably target, where the published evidence for retinal stem-cell programmes really sits today, and how a medical evaluation in Cancún, México decides whether systemic MSC therapy fits your case at all.
Age-related macular degeneration (AMD) is a leading cause of central-vision loss in adults over 50, driven by retinal pigment epithelium (RPE) and photoreceptor dysfunction. The most advanced regenerative trials in AMD use pluripotent stem-cell-derived RPE transplants — not the mesenchymal stem cells (MSC) offered at Cancún regenerative clinics — and remain explicitly investigational in academic Phase 1/2 settings. At Regeneris in Cancún, México, MSC therapy is not promoted as a vision-restoration treatment; it is a systemic, COFEPRIS-regulated intervention that some patients with AMD consider as a complement to ophthalmologic care, after a free medical evaluation and a personalized written plan. We do not publish prices online.
Clinical overview
Age-related macular degeneration (AMD) is a progressive disease of the macula — the central, high-resolution region of the retina — that affects the fine, central vision used for reading, driving, recognising faces, and most close work. It is the leading cause of irreversible central-vision loss in adults over 50 worldwide, and prevalence rises sharply with each decade of life. The disease begins in the retinal pigment epithelium (RPE), the supportive cell layer that nourishes the photoreceptors; as RPE cells dysfunction and die, the overlying photoreceptors follow. Patients in Cancún, México, like patients everywhere, typically first notice difficulty reading small print, distortion of straight lines (the so-called Amsler-grid sign), or a fixed grey patch in the centre of vision. Peripheral vision is generally preserved, but the loss of central detail substantially affects independence.
Clinicians distinguish two main forms. "Dry" (atrophic) AMD is the most common and is characterised by drusen deposits beneath the retina and, in its advanced form, geographic atrophy — patches where the RPE and photoreceptors have died. "Wet" (neovascular) AMD is less common but more aggressive: abnormal blood vessels grow from the choroid into the retina and leak fluid or blood, causing rapid central-vision loss. Wet AMD is currently treated by ophthalmologists with intravitreal anti-VEGF injections, while dry AMD has fewer established options — which is one reason it has become a focus of regenerative-medicine research.
What the research shows
Honest framing matters here. Most headlines about "stem cells for AMD" describe academic Phase 1 and Phase 1/2 trials of PLURIPOTENT stem-cell-derived retinal pigment epithelium (RPE) — either human embryonic stem cell (hESC) lines or induced pluripotent stem cells (iPSC) — surgically transplanted into the subretinal space by retinal surgeons. They are not the same as the mesenchymal stem cell (MSC) therapy offered by regenerative clinics in Cancún, México or anywhere else. Below is a conservative, cited summary of the published landscape so patients can read it on its own terms.
Schwartz and colleagues reported follow-up of two open-label Phase 1/2 studies in which human embryonic stem cell (hESC)-derived RPE cells were transplanted as a subretinal suspension in 9 patients with atrophic AMD and 9 with Stargardt's macular dystrophy. There was no evidence of adverse proliferation, rejection, or serious ocular or systemic safety issues related to the transplanted tissue. This was a SAFETY and feasibility milestone — not proof of broad vision restoration.
Eligibility
Regeneris does not promise vision restoration in AMD, and we do not perform subretinal surgery. Some patients with AMD do explore systemic MSC therapy in Cancún, México as a COMPLEMENT to their ophthalmologist's plan — for example, as part of a broader anti-inflammatory and longevity-oriented protocol, never as a substitute for retina care. The honest list below reflects who is reasonable to evaluate and who should be redirected.
Regulatory framework
Regeneris Therapy operates as a physician-led clinic in Cancún, Quintana Roo, México, under the regulatory framework of COFEPRIS — the Comisión Federal para la Protección contra Riesgos Sanitarios, the Mexican federal health authority (the equivalent of the U.S. FDA). Our Aviso Sanitario (operating notice) is 2323025036X00098 and our Aviso de Publicidad (advertising notice) is 2323022002A00053. Cell therapies are sourced through COFEPRIS-certified laboratory partners; physician oversight is mandatory throughout every protocol.
For patients searching for stem cell therapy in Cancún, México specifically: the COFEPRIS framework is what separates a regulated medical clinic from a wellness or aesthetic centre marketing "stem cell" services without medical accountability. For age-related macular degeneration in particular, where unregulated intra-ocular "stem cell" injections have caused permanent blindness elsewhere, the regulatory distinction matters even more. A reputable clinic in Cancún will be transparent about its avisos, will not promise to restore retinal function, and will document its scope of practice — including the things it does NOT do.
Our approach
Every patient who contacts us about AMD starts with a free medical evaluation — by video or in person at our clinic in Cancún, México. A licensed physician reviews your history, your current ophthalmologic care, recent imaging where available (OCT, fundus photos), and your goals. Only after that conversation do we decide whether systemic MSC therapy is reasonable to consider as an adjunct, whether a peptide or sueroterapia layer fits, or whether the honest answer is that we are not the right setting. There is no auto-yes.
Submit your AMD diagnosis, recent OCT and fundus reports if you have them, the medications you take, and the goals you want to discuss. A Regeneris physician reviews the case and meets with you by video or in person in Cancún.
Your physician explains what regenerative medicine can and cannot reasonably target in AMD — including saying "this is not what we do" when appropriate — and confirms that ophthalmologic care continues unchanged.
If a plan is appropriate, you receive a written, individualized protocol and a personalized written quote covering only that plan. We do not publish prices online because no two cases are identical and we will not anchor your expectations to a number that is not yours.
Realistic expectations
No physician acting in good faith will promise vision restoration from MSC therapy for AMD. The advanced retinal regeneration programmes cited above are surgical, investigational, and conducted by retinal specialists in academic trials — not in regenerative clinics. The disclaimers below are explicit, not legal boilerplate.
FAQ
The questions patients in Cancún, México and abroad ask most about stem cells and age-related macular degeneration.
No. No physician acting in good faith will tell you that stem cells cure age-related macular degeneration. The most advanced regenerative work in AMD — by Schwartz and colleagues in The Lancet (2015), Mandai and Takahashi in the New England Journal of Medicine (2017), and da Cruz and colleagues in Nature Biotechnology (2018) — involves pluripotent stem-cell-derived retinal pigment epithelium (RPE) transplanted surgically into the subretinal space by retinal specialists in academic Phase 1 and Phase 1/2 trials. The primary endpoints in those trials have been safety and feasibility, not cure. Regenerative medicine for AMD remains investigational, and any clinic in Cancún, México or anywhere else that promises to cure AMD with stem cells is overselling.
Continue exploring
The full pillar on mesenchymal stem cell therapy at Regeneris in Cancún, México: cell sources, mechanism, protocols, and how to start.
ContinueHow COFEPRIS regulation, certified labs, and physician oversight differ from unregulated "stem cell" providers — and why it matters in Cancún.
This page is informational and does not constitute medical advice. Mesenchymal stem cell therapy is investigational for many indications, including any role as an adjunct in age-related macular degeneration, and outcomes vary by patient, condition, and protocol. The pluripotent-stem-cell-derived retinal pigment epithelium transplant trials cited (Schwartz 2015, Mandai 2017, da Cruz 2018) are SURGICAL, ACADEMIC programmes conducted by retinal specialists and are not offered at Regeneris. Regeneris does not perform intra-ocular procedures, does not transplant RPE cells, and does not promise vision restoration in AMD. Decisions about regenerative therapy require an individualized evaluation with a licensed physician; disclose all current medications and conditions, and continue all ophthalmologic care. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, México.
Book a free 15-min call with our team.
Send your AMD diagnosis, your recent OCT and fundus reports if you have them, your current medications, and your goals. A Regeneris physician in Cancún will review your case and tell you honestly whether — and how — systemic MSC therapy may fit, with a personalized written quote after your free medical evaluation.
Mandai, Takahashi and colleagues reported the first-in-human transplantation of autologous induced pluripotent stem cell (iPSC)-derived RPE in a patient with neovascular AMD. The transplanted sheet remained intact at one year with no serious adverse events; visual acuity did not improve, but the disease did not progress as expected. The authors and reviewers explicitly framed this as a feasibility case — not as an approved therapy.
Da Cruz and colleagues engineered an hESC-derived RPE monolayer on a synthetic basement membrane and delivered the patch into the subretinal space of two patients with severe exudative AMD. Both patients gained vision (29 and 21 ETDRS letters over 12 months) without serious adverse events attributable to the patch. The authors explicitly characterise the work as a regenerative strategy in early clinical development.
Kuriyan and colleagues documented three patients who suffered severe bilateral vision loss after receiving intravitreal injections of autologous adipose tissue-derived "stem cells" at a U.S. commercial clinic for AMD. Complications included retinal detachment, vitreous haemorrhage, and ocular hypertension; final acuity ranged from 20/200 to no light perception. The case series is widely cited as a warning against unregulated, intra-ocular "stem cell" injections marketed for AMD.
The honest reading of this literature: pluripotent-stem-cell-derived RPE transplantation is a promising research direction, conducted by retinal surgeons in tightly regulated academic trials. It is not the same therapy as systemic MSC infusion at a regenerative clinic, and any clinic claiming to "restore vision in AMD" with intra-ocular stem cell injections outside a registered trial should be treated with extreme caution — including in Cancún, México.
If you proceed, treatment is delivered in our COFEPRIS-regulated clinic in Cancún, México with structured follow-up in coordination with your ophthalmologist — never as a replacement for retina care.
Regeneris does NOT publish prices online for AMD or any other condition. Our model is a free medical evaluation followed by a personalized written quote, so the information you receive is yours — not an average from someone else's case.
No. The academic AMD trials cited use PLURIPOTENT stem cells (human embryonic stem cell or induced pluripotent stem cell lines) differentiated into retinal pigment epithelium and surgically transplanted into the eye by retinal specialists. Regeneris offers MESENCHYMAL stem cell (MSC) therapy — a different cell type, delivered systemically (intravenously) or locally, not into the eye. MSC therapy acts through paracrine signalling on inflammation and the regenerative environment across the whole body. We do not transplant RPE cells and we do not perform intra-ocular procedures for AMD in Cancún, México or elsewhere.
No — and not from us. Kuriyan and colleagues documented three patients in the New England Journal of Medicine (2017) who suffered severe bilateral vision loss after intravitreal injections of autologous adipose-derived "stem cells" at a U.S. commercial clinic for AMD; complications included retinal detachment, vitreous haemorrhage, and ocular hypertension, with final visual acuity ranging from 20/200 to no light perception. Outside a registered, regulated clinical trial run by retinal specialists, intra-ocular "stem cell" injections for AMD are dangerous. If a clinic in Cancún, México (or anywhere) offers this, walk away and consult a retinal specialist.
It depends on the goal and on whether you are an appropriate candidate after evaluation. Some patients with AMD pursue systemic MSC therapy at Regeneris in Cancún, México as a complement to their ophthalmologist's plan — typically as part of a broader anti-inflammatory and longevity-oriented protocol. It is not a vision-restoration treatment, it is not a replacement for ophthalmologic care, and it is not appropriate for every patient. Whether it fits at all — and what realistic expectations are — is a conversation that happens in your free medical evaluation, with your ophthalmologist informed throughout.
No — and you should not. AMD requires ongoing ophthalmologic care: anti-VEGF injections for neovascular AMD, AREDS2-style nutritional and lifestyle support and timely monitoring for atrophic AMD, and structured follow-up imaging in both. Regenerative therapy at Regeneris, if pursued at all, is a SYSTEMIC adjunct delivered in coordination with — never as a replacement for — your retinal specialist. If a clinic anywhere tells you to stop seeing your ophthalmologist, that is a serious red flag.
Because AMD presents differently in every patient and our model is medical, not transactional. We do not anchor your expectations to an internet number that is not yours, and we do not let a price decide before a physician has reviewed your case. The process at Regeneris is the same for every condition: a free medical evaluation in Cancún, México (by video or in person), an honest scope conversation about what is and is not appropriate, and — only if a plan is appropriate — a personalized written quote covering only that plan. You will not be quoted a number before a Regeneris physician has reviewed your case and written your plan down.
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.